Early reversal of rapacuronium with neostigmine

Area of Science:

• Anesthesiology and Pharmacology
• Neuromuscular Blockade and Reversal Agents

Background:

• Rapacuronium is a rapid-onset, short-acting neuromuscular relaxant used in anesthesia.
• Understanding optimal reversal strategies is crucial for patient recovery and safety.

Purpose of the Study:

• To determine the effect of early neostigmine administration on neuromuscular recovery following rapacuronium blockade.
• To compare different timings (2 vs. 5 minutes) and doses (0.05 vs. 0.07 mg/kg) of neostigmine for reversal.

Main Methods:

• A multi-center study involving 117 patients randomized to receive varying doses of rapacuronium and neostigmine.
• Neuromuscular block assessed via mechanomyography of adductor pollicis response to ulnar nerve stimulation (train-of-four).
• Neostigmine administered 2 or 5 minutes post-rapacuronium, with recovery compared to a control group.

Main Results:

• Both rapacuronium doses (1.5 and 2.5 mg/kg) induced profound neuromuscular block (97-100%).
• Neostigmine significantly accelerated recovery in all treatment groups compared to controls.
• Recovery times (T1 and train-of-four ratio) were similar across different neostigmine doses and administration timings.

Conclusions:

• Early administration of neostigmine effectively accelerates recovery from intense rapacuronium-induced neuromuscular block.
• Neostigmine given 2 minutes post-rapacuronium was as effective as when given at 5 minutes.
• A neostigmine dose of 0.05 mg/kg was comparable in efficacy to 0.07 mg/kg for reversing rapacuronium block.